Garry Arthur Neil - Net Worth and Insider Trading
Garry Arthur Neil Net Worth
The estimated net worth of Garry Arthur Neil is at least $359,909 dollars as of 2024-04-28. Garry Arthur Neil is the Chief Scientific Officer of Aevi Genomic Medicine Inc and owns about 2,164,150 shares of Aevi Genomic Medicine Inc (GNMX) stock worth over $359,032. Garry Arthur Neil is also the CEO and Chairman of the Board of Avalo Therapeutics Inc and owns about 55 shares of Avalo Therapeutics Inc (AVTX) stock worth over $877. Details can be seen in Garry Arthur Neil's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Garry Arthur Neil has not made any transactions after 2023-06-09 and currently still holds the listed stock(s).
Transaction Summary of Garry Arthur Neil
Garry Arthur Neil Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Garry Arthur Neil owns 6 companies in total, including Arena Pharmaceuticals Inc (ARNA) , Avalo Therapeutics Inc (AVTX) , and Aevi Genomic Medicine Inc (GNMX) among others .
Click here to see the complete history of Garry Arthur Neil’s form 4 insider trades.
Insider Ownership Summary of Garry Arthur Neil
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| ARNA | Arena Pharmaceuticals Inc | 2020-06-12 | director |
| AVTX | Avalo Therapeutics Inc | 2023-06-09 | Chief Medical Officer |
| GNMX | Aevi Genomic Medicine Inc | 2020-02-03 | Chief Scientific Officer |
| ONCT | Oncternal Therapeutics Inc | 2016-08-31 | director |
| CLDX | Celldex Therapeutics Inc | 2023-06-15 | director |
| ZURA | Zura Bio Ltd | 2023-03-20 | director |
Garry Arthur Neil Latest Holdings Summary
Garry Arthur Neil currently owns a total of 2 stocks. Among these stocks, Garry Arthur Neil owns 2,164,150 shares of Aevi Genomic Medicine Inc (GNMX) as of December 5, 2019, with a value of $359,032 and a weighting of 99.76%. Garry Arthur Neil also owns 55 shares of Avalo Therapeutics Inc (AVTX) as of June 9, 2023, with a value of $877 and a weighting of 0.24%.
Latest Holdings of Garry Arthur Neil
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| GNMX | Aevi Genomic Medicine Inc | 2019-12-05 | 2,164,150 | 0.17 | 359,032 |
| AVTX | Avalo Therapeutics Inc | 2023-06-09 | 55 | 15.94 | 877 |
Holding Weightings of Garry Arthur Neil
Garry Arthur Neil Form 4 Trading Tracker
According to the SEC Form 4 filings, Garry Arthur Neil has made a total of 1 transactions in Aevi Genomic Medicine Inc (GNMX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Aevi Genomic Medicine Inc is the acquisition of 2,049,376 shares on December 5, 2019, which cost Garry Arthur Neil around $266,419.
According to the SEC Form 4 filings, Garry Arthur Neil has made a total of 6 transactions in Avalo Therapeutics Inc (AVTX) over the past 5 years, including 6 buys and 0 sells. The most-recent trade in Avalo Therapeutics Inc is the acquisition of 17 shares on June 9, 2023, which cost Garry Arthur Neil around $13,680.
Insider Trading History of Garry Arthur Neil
- 1
Garry Arthur Neil Trading Performance
GuruFocus tracks the stock performance after each of Garry Arthur Neil's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Garry Arthur Neil is -31.46%. GuruFocus also compares Garry Arthur Neil's trading performance to market benchmark return within the same time period. The performance of stocks bought by Garry Arthur Neil within 3 months outperforms 1 times out of 7 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Garry Arthur Neil's insider trading performs compared to the benchmark.
Performance of Garry Arthur Neil
Average Return
-43.34%
Outperforming Transactions
33%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -14.55 | -31.46 | -26.8 | -43.34 | -70.4 | -69.16 |
| Relative Return to S&P 500(%) | -16.06 | -34.22 | -33.45 | -53.95 | -74.79 | -78.34 |
Garry Arthur Neil Ownership Network
Ownership Network List of Garry Arthur Neil
Ownership Network Relation of Garry Arthur Neil
Garry Arthur Neil Owned Company Details
What does Arena Pharmaceuticals Inc do?
Who are the key executives at Arena Pharmaceuticals Inc?
Garry Arthur Neil is the director of Arena Pharmaceuticals Inc. Other key executives at Arena Pharmaceuticals Inc include director & President and CEO Amit Munshi , EVP & Chief Commercial Officer Robert Lisicki , and Executive VP and CBO Vincent Aurentz .
Arena Pharmaceuticals Inc (ARNA) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Arena Pharmaceuticals Inc (ARNA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Arena Pharmaceuticals Inc (ARNA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Arena Pharmaceuticals Inc (ARNA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Arena Pharmaceuticals Inc Insider Transactions
Garry Arthur Neil Mailing Address
Above is the net worth, insider trading, and ownership report for Garry Arthur Neil. You might contact Garry Arthur Neil via mailing address: 555 California Street, Suite 365, San Francisco Ca 94104.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
